Last updated: May 4, 2026
What is MODURETIC 5-50 and what is its current clinical development status?
MODURETIC 5-50 is a fixed-dose combination of amiloride hydrochloride 5 mg and hydrochlorothiazide (HCTZ) 50 mg indicated for hypertension. The product is an established, off-patent combination; current commercial supply is maintained by ongoing manufacturing and lifecycle management rather than new pivotal clinical programs.
Clinical trials: what is publicly visible
No active, high-enrollment, late-stage (Phase 3) trials specific to MODURETIC 5-50 were identified as current in the public trial registries used for cross-industry monitoring in the last reporting cycle. Publicly visible research activity is typically limited to:
- Bioequivalence / formulation work for generics or authorized products
- Observational studies using amiloride-HCTZ combinations in real-world hypertension care
- Mechanistic or safety studies that evaluate diuretic classes rather than the exact branded 5-50 dose strength
Because MODURETIC 5-50 is a legacy branded combination with no ongoing late-stage branded development signal, the clinical-trials “update” for business planning is best treated as trial noise vs. actionable differentiation: the evidentiary basis for label maintenance remains the existing hypertension pharmacology and prior clinical literature, with limited incremental impact from new trials that do not change the therapeutic claim.
How does MODURETIC 5-50 compete in the hypertension market?
Hypertension treatment is dominated by large, entrenched classes that drive most prescribing volume:
- ACE inhibitors
- ARBs
- Calcium channel blockers
- Thiazide-type diuretics (including HCTZ and chlorthalidone where preferred)
- Beta blockers (in specific subpopulations)
- Fixed-dose combinations (FDC) across classes for adherence
MODURETIC 5-50 competes on:
- Use case fit where clinicians target diuresis with potassium-sparing support (amiloride offsets hypokalemia risk seen with thiazides alone)
- Cost and formulary position versus newer combination products
- Clinical familiarity in primary care and chronic care settings
Where MODURETIC has a structural advantage
- Potassium-sparing profile within a diuretic regimen: The amiloride component reduces potassium losses associated with HCTZ. This aligns with clinician concerns about thiazide-induced hypokalemia.
- Simplified regimen: A single FDC tablet improves adherence versus splitting diuretic and potassium management.
Where MODURETIC faces structural headwinds
- Dose modernity and tolerability preferences: Many markets and prescribers have shifted toward lower HCTZ strengths (and/or chlorthalidone in some systems) due to updated practice patterns and comparative outcomes considerations for thiazide-type diuretics.
- Switching to class FDCs: ARB/ACEi + diuretic and ACEi/ARB + CCB fixed-dose combos capture adherence demand.
- Generic penetration: The amiloride-HCTZ combo is widely generically available in many jurisdictions, compressing brand economics.
What does the market analysis indicate for MODURETIC 5-50?
Market demand drivers
Hypertension prevalence and long-term treatment adherence remain steady demand drivers. The share of diuretic-based therapy remains large globally, with thiazide-type diuretics embedded in guidelines and practice.
MODURETIC 5-50 demand is influenced by:
- Formulary access for a potassium-sparing diuretic combination
- Generic pricing dynamics
- Local prescribing guidelines that specify preferred thiazide-type diuretics and dosing approaches
- Safety monitoring capacity (electrolytes, renal function)
Competitive set (functional substitutes)
MODURETIC 5-50’s substitutes are typically:
- HCTZ monotherapy (with separate potassium replacement or monitoring)
- Chlorthalidone-based regimens (where preferred)
- Other potassium-sparing diuretics (triamterene, spironolactone/eplerenone in selected indications)
- Cardiometabolic FDCs that combine diuretic effects with RAAS inhibition or calcium channel blockade
Commercial implication
Given the fixed-dose nature, weak differentiation (no new mechanism), and generic availability, MODURETIC’s branded revenue trajectory generally tracks:
- Modest volume stability in established prescribing bases
- Erosion risk from further generic substitution and from preferential use of other diuretic or class FDC products
What are the near-term and medium-term projections for MODURETIC 5-50?
Because MODURETIC 5-50 is an established product with no active late-stage branded development signal, projections focus on brand share and pricing, not launch of new clinical value.
Projection framework (what business planning should assume)
- Base case: Stable hypertension prevalence-driven demand, offset by generic price pressure and prescriber migration to other FDC options.
- Downside case: Continued formulary tightening against legacy fixed-dose strengths and increased switching to lower HCTZ strengths or alternative thiazide-type diuretics.
- Upside case: Sustained formulary inclusion driven by clinician confidence in potassium-sparing diuretic regimens and stable renal/electrolyte monitoring outcomes.
What this means for revenue and demand
For business planning, the most realistic pattern for a legacy branded diuretic FDC is:
- Volume: Stable to slightly declining (years-long prescribing inertia balanced by gradual substitution)
- Price: Downward due to generic compression and discounting
- Net market: Gradual brand erosion unless rebundling or contractual protections preserve market share
Are there any label changes, safety signals, or regulatory developments that matter for market positioning?
MODURETIC’s label safety profile is dominated by expected diuretic class risks:
- Electrolyte abnormalities (notably hypokalemia mitigated by amiloride; risk still exists depending on patient factors)
- Hyponatremia
- Renal function changes
- Hyperuricemia/gout flares in susceptible patients
For positioning, these risks matter mainly for adherence and monitoring requirements, not for a new regulatory discontinuity. In established diuretic products, label updates tend to be incremental and do not typically reset market structure.
Investment and R&D implications
If you are evaluating MODURETIC as an acquisition target
- You are buying a legacy, low-IP-risk cash flow stream tied to formulary positioning.
- Value hinges on contracted brand retention, channel dynamics, and local generic competitive intensity.
If you are evaluating MODURETIC as a platform for lifecycle differentiation
- Differentiation through new clinical endpoints is unlikely without new IP or regulatory pathway changes.
- Differentiation is more feasible through formulation, dosing optimization, and combination strategy (for example, lower-strength HCTZ or alternate diuretic pairs) rather than the exact 5-50 branded configuration.
Key Takeaways
- MODURETIC 5-50 is an established amiloride 5 mg + HCTZ 50 mg hypertension FDC with limited visibility of late-stage branded clinical development.
- Public trial activity is more likely to be bioequivalence and observational work than new Phase 3 branded evidence.
- Market demand remains supported by the durability of thiazide-type diuretics in hypertension care, but MODURETIC faces generic pricing pressure and prescriber migration to modern fixed-dose regimens.
- Projections for the branded product are best modeled as stable-to-declining brand share with falling realized price, unless formulary protections preserve positioning.
FAQs
1) Is MODURETIC 5-50 currently in Phase 3 development?
Publicly visible late-stage branded development signal for the exact MODURETIC 5-50 combination is not evident in recent registry screening.
2) What differentiates MODURETIC from HCTZ monotherapy?
Its differentiation is amiloride’s potassium-sparing effect, which reduces thiazide-associated potassium loss risk versus HCTZ alone.
3) What are the most likely substitutes that steal share?
Functional substitutes include thiazide-type diuretics, other potassium-sparing diuretics, and modern fixed-dose combinations that pair diuretic action with RAAS blockade or CCB therapy.
4) What is the main business risk for a legacy branded diuretic FDC?
The main risk is generic compression and formulary substitution away from older branded dose strengths toward preferred diuretic regimens and class FDCs.
5) What is the main business lever to defend market position?
Formulary access and channel contracting, supported by clinician familiarity with potassium-sparing diuretic regimens and monitoring adherence.
References
[1] U.S. National Library of Medicine. ClinicalTrials.gov. https://clinicaltrials.gov/
[2] FDA. Drug labeling and prescribing information resources (access portal). https://www.accessdata.fda.gov/
